Inclusion Criteria:

        Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or
        B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma).

        Phase 2a Inclusion

          -  Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL
             includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL
             with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or
             refractory.

          -  Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease
             afterwards.

          -  Prior treatment for lymphoid malignancy for progressive /refractory disease

          -  ≥ 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or
             TKI alone or in combination.

          -  Measureable disease defined as: ≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET
             with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's
             macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0

          -  Ability to provide diagnostic reports

        General Inclusion

          -  ECOG Score of 0 or 1.

          -  Hematologic ANC > 1000/uL and platelet > 75,000/uL,

          -  Serum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min

          -  Bilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN

        Exclusion Criteria:

          -  Richter's syndrome, Burkitt's lymphoma, or Burkitt-like Lymphoma (transformed DLBCL
             from Follicular NHL are eligible).

          -  Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment
             within 8 weeks of Day 1.

          -  Prior therapy with SYK inhibitors.

          -  Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton
             pump inhibitors

          -  Known lymphomatous involvement of the CNS.

          -  Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2, previous drug-related toxicity
             (except alopecia, erectile impotence, hot flashes, libido, neuropathy).

          -  Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate,
             phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or
             any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1.

          -  For CTCL: (TSEBT) within 12 weeks, or initiation of topical steroid, nitrogen mustard,
             or topical retinoid within 2 weeks. (Stable topical ≥ 4 weeks prior to Day 1 allowed).

          -  Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be
             HBsAg- or undetectable DNA

          -  Active infection requiring systemic treatment,

          -  Significant GI disease, previous major gastric/bowel surgery, difficulty swallowing or
             malabsorption syndrome.

          -  Major surgery within 4 weeks

          -  Previous malignancies within 2 yrs. unless relapse risk is small (< 5%).

          -  Current use of systemic steroids >20 mg QD prednisone (or equivalent)

          -  Breastfeeding or pregnant (intention to become) females or participation in other
             clinical trials